Clinical trials in diffuse large B cell lymphoma

Strike action between Monday 2 October to Thursday 5 October 2023

Consultants and junior doctors at The Christie will both strike between 7am on Monday 2 October to 7am on Thursday 5 October 2023. Both consultants and junior doctors will still provide emergency care during their strikes.

We are proactively contacting patients with appointments that may be affected by this strike. If you have an appointment at the Trust on any of these dates, please continue to come to The Christie and our other centres as planned unless we contact you to tell you otherwise. There may be longer waits than usual in clinics during this time.

Please do not call to check if your appointment is still going ahead.

The list below shows The Lymphoma Group's current clinical trials open/due to open for recruitment for Diffuse large B-cell lymphoma patients.

If you would like to know how to access our trials, please see how to contact us.

GEN3013 - Phase 1/2 study using antibody GEN3013 to target CD20- expressing cells in patients with B cell non Hodgkin lymphoma

Suitable for patients with B cell non-Hodgkin lymphoma which has come back after previous treatment
JCAR017 - Phase 2 study determining efficacy and safety of JCAR017

Suitable for patients with lymphoma which has come back after previous treatment
GO29781 - A phase 1/1b trial testing mosunetuzumab, on its own or with atezolizumab

Suitable for patients with lymphoma which has come back after previous treatment
GCT3013-02 - A phase 1b/2 trial of a targeted treatment, epcoritamab, in combination with different chemotherapy regimens, in people with B-cell non-Hodgkin lymphoma.
LOTIS-3 - A phase 1/2 trial of loncastuximab tesirine and ibrutinib in people with relapsed or refractory diffuse large B-cell lymphoma or mantle cell lymphoma.

With special thanks to the following:

Strike action between Monday 2 October to Thursday 5 October 2023

Clinical trials in diffuse large B cell lymphoma

Last updated: March 2023